✦ LIBER ✦

Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian Cancer

✍ Scribed by Giorgio Bolis; Giovanna Scarfone; Giorgio Giardina; Antonella Villa; Giorgia Mangili; Mauro Melpignano; Mauro Presti; Saverio Tateo; Massimo Franchi; Fabio Parazzini

Book ID: 112248452
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 73 KB
Volume: 81
Category: Article
ISSN: 0090-8258
DOI: 10.1006/gyno.2001.6151

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Paclitaxel vs Epidoxorubicin plus Paclit

Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer

✍ Giorgio Bolis; Fabio Parazzini; Giovanna Scarfone; Antonella Villa; Mariangela A 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 46 KB

SCOTROC 2B: feasibility of carboplatin f

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer

✍ Clamp, A R; Mäenpää, J; Cruickshank, D; Ledermann, J; Wilkinson, P M; Welch, R; 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 119 KB

Phase II study of gefitinib in combinati

Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)

✍ Patricia Pautier; Florence Joly; Pierre Kerbrat; Philippe Bougnoux; Pierre Fumol 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 283 KB

776 An economic analysis of the TAX 326

776 An economic analysis of the TAX 326 trial: a multicenter randomized study of docetaxel + cisplatin (DC) or docetaxel + carboplatin (DCb) vs. vinorelbine + cisplatin (VC) as first-line therapy in advanced non-small cell lung cancer (NSCLC)

✍ N. Leighl; F.A. Shepherd; W.S. Tsao; P. Lindgren; C.B. Belani; F.V. Fossella; P. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 336 KB

An open-label, single-arm Phase II study

An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer

✍ Peter G. Rose; Bradley J. Monk; Diane Provencher; Jean Hartney; Philippe Legenne 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 192 KB